Literature DB >> 33288598

Prognostic Factors of Local Control and Survival in Patients Irradiated for Glioblastoma Multiforme (GBM).

Jaspar Witteler1, Steven E Schild2, Dirk Rades3.   

Abstract

BACKGROUND/AIM: Standard treatment of glioblastoma multiforme (GBM) includes resection, longer-course radiotherapy and chemotherapy. Some patients cannot tolerate these regimens and may benefit from personalized treatments. This study aims to contribute to treatment personalization by identifying predictors of outcomes after longer-course radiotherapy. PATIENTS AND METHODS: In 91 patients, number/site/diameter of lesions, Ki-67, MGMT promoter methylation, Karnofsky performance score (KPS), symptoms, gender, age and resection were evaluated for local control and survival.
RESULTS: On univariate analyses, gross resection (p=0.029) was significantly associated with improved local control. It maintained significance in the multivariate analysis [hazard ratio (HR)=1.64, p=0.025]. MGMT-methylation (p=0.004), KPS ≥80 (p=0.022) and resection (p<0.001) were significantly associated with improved survival on univariate analyses, unifocal GBM (p=0.056) showed a trend. In the multivariate analyses, MGMT-methylation (HR=3.63, p=0.009), KPS (HR=2.01, p=0.018) and resection (HR=3.29, p<0.001) were significant.
CONCLUSION: Predictors of local control and survival were identified that may guide physicians when tailoring treatments to patients with GBM.
Copyright © 2020 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Glioblastoma multiforme; local control; longer-course radiotherapy; prognostic factors; survival

Mesh:

Year:  2020        PMID: 33288598     DOI: 10.21873/anticanres.14728

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  1 in total

1.  Risk Factors for Sleep Problems Prior to Radiochemotherapy for Malignant Gliomas.

Authors:  Svenja Kopelke; Troels W Kjaer; Soeren Tvilsted; Steven E Schild; Tobias Bartscht; Dirk Rades
Journal:  In Vivo       Date:  2022 Jan-Feb       Impact factor: 2.155

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.